REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • April 28th, 2021 • Relay Therapeutics, Inc. • Biological products, (no disgnostic substances) • Delaware
This Registration Rights Agreement (this “Agreement”) is made and entered into as of April 22, 2021 (the “Effective Date”) by and among Relay Therapeutics, Inc., a Delaware corporation (the “Company”), the equity holders of ZebiAI Therapeutics, Inc., a Delaware corporation (“ZebiAI”), party hereto (each, a “Stockholder” and, together with any permitted transferee of Registrable Securities hereunder, collectively, the “Stockholders”), and Computershare Trust Company, N.A.
Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. Information that was omitted has been noted in this document with a placeholder...Collaboration and License Agreement • April 28th, 2021 • Relay Therapeutics, Inc. • Biological products, (no disgnostic substances)
This Amendment No. AR1 to the Amended and Restated Collaboration and License Agreement (the “Amendment No. AR1”), effective as of February 4, 2021 (the “Amendment No. AR1 Effective Date”), is by and between D. E. Shaw Research, LLC, a Delaware limited liability company located at 120 West 45th Street, 39th Floor, New York, NY 10036 (“DESRES”), and Relay Therapeutics, Inc., a Delaware corporation located at 399 Binney Street, Cambridge, MA 02139 (“Company”). DESRES and Company are each sometimes referred to herein as a “Party” or collectively as the “Parties”.
